Oncology Drug Approval - Accelerated

Bridging the gap between biomarkers and In Vitro Companion Diagnostics

Technologies & Platforms

At MolecularMD we use the best tools for the job because we know how important it is to accelerate the approval and commercialization of your therapies. Our solutions are designed to support all phases of your oncology drug development process as well as to adapt rapidly to any changes in your strategies.

And by remaining platform agnostic, we are able to select the most appropriate technology and platform to establish the desired specifications for our assays and meet all your criteria. Some of our latest assays have been developed employing exciting new technologies such as droplet digital PCR (ddPCR) and next-generation sequencing (NGS).



Biomarker Assay


Bio-Rad QX100™/QX200™

Copy Number | Gene Expression | Mutations


Ventana Benchmark XT

Ventana Benchmark ULTRA

Leica Bond III

Protein Expression


nanoString nCounter®

Copy Number | Gene Expression

Next Generation Sequencing

Illumina MiSeq

Ion PGM™ System

Ion S5

Copy Number | Mutations | RNA Fusions


Applied Biosystems 7500 & QuantStudio™

Bio-Rad CFX96™

Qiagen Rotor-Gene Q

Mutations | Gene Expression

Sanger Sequencing

Applied Biosystems 3730xl DNA Analyzer


Read the brochure or watch the short video to learn how MolecularMD develops and commercializes molecular diagnostics for oncology applications.